To access this element change to forms mode OFF
Grant Award View - GA276597
Repurposing the in-clinic PCSK9 inhibitor evolocumab to enhance...
GA ID:
GA276597
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
27-Oct-2022
Publish Date:
19-Dec-2022
Category:
Medical Research
Grant Term:
1-Jan-2023 to 31-Dec-2025
Value (AUD):
$532,570.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 21/22 1.1 Health and Medical Research
Grant Program:
Ideas Grants
Grant Activity:
Repurposing the in-clinic PCSK9 inhibitor evolocumab to enhance Gemcitabine/Abraxane chemotherapy in pancreatic cancer guided by single-cell intravital imaging
Purpose:
During pancreatic cancer development, cancer cells undergo metabolic rewiring in order to survive, grow and spread. This Ideas Grant will use advanced animal imaging and unique patient-derived pancreatic cancer specimens to explore targeting PCSK9 with drugs already in the clinic, in combination with chemotherapy. This new dual therapy could significantly improve treatment response in this devastating disease.
GO ID:
GO Title:
Ideas Grants 2022
Internal Reference ID:
2022/GNT2019139
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of New South Wales
Recipient ABN:
57 195 873 179
Grant Recipient Location
Suburb:
Kensington
Town/City:
Kensington
Postcode:
2052
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
ACT, NSW, Overseas
Postcode:
Multiple
Country:
AUSTRALIA, UNITED KINGDOM